Q-omics provides the consensus-scored MTCYBP24 profile across patient tissues and cancer cell-line models. MTCYBP24 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MTCYBP24 is differentially expressed in 3, with the highest sampling consensus in LIHC. Additionally, MTCYBP24 RNA expression shows 5,898 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, LIHC, and STAD as cancer lineages where MTCYBP24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP24 survival associations across molecular data types. MTCYBP24 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP24 RNA expression–survival associations across cancer types. High MTCYBP24 expression shows unfavorable associations in UCEC, STAD, UCS and UVM, but favorable associations in LUSC and LAML. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for MTCYBP24 RNA expression.
This table summarizes MTCYBP24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP24 shows lower tumor expression in THCA and KIRC and higher tumor expression in LIHC. The LIHC box plot shows higher MTCYBP24 RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p = .004).
This table shows molecular features associated with MTCYBP24 in patient tissues and cancer cell lines. In patient samples, MTCYBP24 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
